Prioritizing BCMA-Targeted Therapies in Early Relapsed Multiple Myeloma

Accumulating clinical trial data demonstrating overall survival benefits over standard regimens confirm that B-cell maturation antigen (BCMA)-targeted agents should be the preferred therapeutic approach for multiple myeloma in the second line and beyond, according to Hans Lee, MD, director of Multiple Myeloma Research at Sarah Cannon Research Institute in Nashville, Tennessee. When evaluating patients in early relapse, care teams can choose between 2 highly effective BCMA-directed modalities: chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies. Because treatment selection is not one-size-fits-all, clinicians must weigh the distinct logistical, administration, and accessibility trade-offs of each platform to tailor care to the individual.

CAR T-cell therapy offers a uniquely valuable treatment paradigm characterized by a single infusion that can yield deep, durable remissions and extended treatment-free intervals lasting months to years. However, this option requires significant upfront logistics, because patients must reside near or travel to a specialized cellular therapy center for care. Patients must also undergo apheresis, bridging therapy, and wait through cell manufacturing before final infusion.

Conversely, off-the-shelf bispecific antibodies provide immediate, highly potent BCMA targeting without manufacturing delays, making them crucial for rapidly progressive disease and expanding overall treatment access. The practical delivery of bispecific antibodies continues to improve as toxicity management protocols evolve. For instance, incorporating prophylactic tocilizumab (Actemra) prior to the initial step-up dose significantly mitigates early cytokine release syndrome, enhancing patient safety.

Lee emphasizes that bispecific antibodies can and should be delivered within community oncology practice settings. Although successful community administration requires internal team organization and structured action plans to manage step-up dosing and potential toxicities, establishing these workflows is essential for expanding access to lifesaving BCMA-targeted therapies for patients unable to travel to academic medical centers.